Free Trial
TSE:EXE

Extendicare (EXE) Stock Price, News & Analysis

Extendicare logo
C$10.14 +0.13 (+1.30%)
(As of 11/15/2024 08:56 PM ET)

About Extendicare Stock (TSE:EXE)

Key Stats

Today's Range
C$9.99
C$10.20
50-Day Range
C$8.66
C$10.18
52-Week Range
C$6.41
C$10.43
Volume
155,352 shs
Average Volume
134,798 shs
Market Capitalization
C$846.39 million
P/E Ratio
14.91
Dividend Yield
4.73%
Price Target
C$9.50
Consensus Rating
Hold

Company Overview

Extendicare Inc., through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties. It operates through the Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. The company was incorporated in 1968 and is based in Markham, Canada.

Extendicare Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

EXE MarketRank™: 

Extendicare scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Extendicare has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Extendicare has only been the subject of 1 research reports in the past 90 days.

  • Read more about Extendicare's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Extendicare is 14.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.30.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Extendicare is 14.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.45.

  • Price to Book Value per Share Ratio

    Extendicare has a P/B Ratio of 7.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Extendicare's valuation and earnings.
  • Short Interest

    There is no current short interest data available for EXE.
  • Dividend Leadership

    Extendicare is a leading dividend payer. It pays a dividend yield of 5.14%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Extendicare does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Extendicare is 70.59%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Extendicare's dividend.
  • Short Interest

    There is no current short interest data available for EXE.
  • News Sentiment

    Extendicare has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Extendicare this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for EXE on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Extendicare insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 19.16% of the stock of Extendicare is held by institutions.

  • Read more about Extendicare's insider trading history.
Receive EXE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter.

EXE Stock News Headlines

Leede Financial Predicts Increased Earnings for Extendicare
Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?
Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?
Extendicare (EXE) Scheduled to Post Quarterly Earnings on Tuesday
Where to Invest $5,000 in October
See More Headlines

EXE Stock Analysis - Frequently Asked Questions

Extendicare's stock was trading at C$7.28 at the beginning of 2024. Since then, EXE shares have increased by 39.3% and is now trading at C$10.14.
View the best growth stocks for 2024 here
.

Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE).

Company Calendar

Ex-Dividend for 10/15 Dividend
9/27/2024
Dividend Payable
10/15/2024
Ex-Dividend for 11/15 Dividend
10/31/2024
Dividend Payable
11/15/2024
Today
11/17/2024
Next Earnings (Estimated)
3/06/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Care Facilities
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
23,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$9.50
High Stock Price Target
C$10.50
Low Stock Price Target
C$8.50
Potential Upside/Downside
-6.3%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
C$59.44 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$1.39 billion
Cash Flow
C$3.17 per share
Book Value
C$1.28 per share

Miscellaneous

Free Float
N/A
Market Cap
C$846.39 million
Optionable
Not Optionable
Beta
1.26
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (TSE:EXE) was last updated on 11/18/2024 by MarketBeat.com Staff
From Our Partners